Previous Review

The 1st China BioMed Innovation and Investment Conference

The 2016 China BioMed Innovation and Investment Conference (CBIIC) was successfully co-hosted by China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Securities Association of China (SAC) at Suzhou on November 14-16, 2016. Under the theme of “Promote the Linkage between Social Capital and Innovation, Improve the Innovation Capability of Pharmaceutical Industry”, the 2016 CBIIC set new stages including keynote speeches, panel discussion between scientists and investors, clinical trial data release of innovative drugs, panel discussion, roadshows for pharmaceutical enterprises, and policy sharing forum, focused on and discussed important issues related to pharmaceutical industry and investment policies, trends of innovative drugs R&D, and investment in pharmaceutical industry. Moreover, the 2016 CBIIC debuted data of clinical trials of first-in-class drugs made in China and beyond, making itself the first non-professional conference releasing data of research-based clinical trials, fully demonstrating the event gained great recognition and praise from leaders of pharmaceutical innovation, making the stage the brightest spot of the conference.

The 2nd China BioMed Innovation and Investment Conference

The 2017 China BioMed Innovation and Investment Conference (CBIIC) was successfully co-hosted by PhIRDA, SAC, China Association for Medical Devices Industry (CAMDI) and Hong Kong Exchanges and Clearing Limited (HKEX) at Suzhou on October 29-31, 2017. 2017 CBIIC set clinical trial data release of innovative drugs, roadshows for domestic and overseas drugs and medical devices, and forums of China’s pharmaceutical innovative policies and investment experience sharing, focused on and discussed important issues about latest China’s pharmaceutical and investment policies, trends of drug R&D, and direction of innovative investment. Moreover, the 2017 CBIIC set the roadshow for international innovative projects for the first time, added roadshows for medical devices and investor’s experience sharing, making the conference an important platform for exchanges and cooperation of international pharmaceutical innovation and investment and promoting the innovative development of pharmaceutical industry in all respects.

The 3rd China BioMed Innovation and Investment Conference

The 2018 China BioMed Innovation and Investment Conference (CBIIC) was successfully co-hosted by PhIRDA, CAMDI, Chinese Hospital Association (CHA), and HKEX on September 18-20, 2018 at Suzhou. Under the theme of “Promote the Capitalization and Industrialization of Pharmaceutical Innovative Achievements by Encouraging the Investment of Social Capital in Pharmaceutical Innovation Field and Facilitating the Transformation of Pharmaceutical Innovative Achievements to Meet Unmet Clinical Needs”, 2018 CBIIC added roadshows for rare diseases and orphan drugs and artificial intelligence, which are of great attention, set forum concerning cross-border M&A, closed meetings and many activities to focus on and discuss important issues including latest pharmaceutical and investment policies, trends of drug R&D, and direction for innovative investment. The conference has become a brand event in the pharmaceutical innovation and investment industry receiving great attention of Asian countries, and generating extensive influence in the international community.

The 4th China BioMed Innovation and Investment Conference

The 2019 China BioMed Innovation and Investment Conference (CBIIC) was successfully co-hosted by PhIRDA, CHA, CAMDI, HKEX and Research and Development International (RDI) at Suzhou on September 21-23, 2019. Under the theme of “Promote the Linkage between Domestic and International Social Capital and Innovation, Improve the Innovation Capability of China’s Pharmaceutical Industry”, 2019 CBIIC closely centered on important issues including current background of pharmaceutical innovative policies and investment trends, invited government officials, KOLs from domestic and international pharmaceutical and investment industry, and set roadshows for domestic and international innovative pharmaceutical projects, and forums for topics including investor’s experience sharing, pharmaceutical policy, gaining high praise from pharmaceutical and investment industry, and receiving warm feedback and constant attention at home and abroad.

The 5th China BioMed Innovation and Investment Conference

The 2020 China BioMed Innovation and Investment Conference (CBIIC) was successfully co-hosted by PhIRDA, CAMDI, HKEX and iMeta Health Information Consulting (iMeta) at Suzhou on September 27-29, 2020. Following the purpose of “Promote the Linkage between Domestic and International Social Capital and Innovation, Improve the Innovation Capability of China’s Pharmaceutical Industry”, 2020 CBIIC focused on the direction of China’s pharmaceutical innovation and investment and financing in a post-pandemic era, demonstrating the country’s strong vitality in pharmaceutical innovation; build an effective, and precisely matched high-level platform of exchanges and cooperation for pharmaceutical innovative projects, scientists, and investors at home and abroad; continue to step up cooperation with related government agencies, renowned institutions in China and beyond to further improve the capabilities of pharmaceutical industry’s transformation of innovative research results .

The 6th China BioMed Innovation and Investment Conference

The 2021 China BioMed Innovation and Investment Conference (CBIIC) was successfully co-hosted by PhIRDA, HKEX, RDI, and iMeta at Suzhou on September 25-27, 2021. The 2021 CBIIC continued to explore channels of pharmaceutical innovation and investment and financing, centered on the popular issues including pharmaceutical innovation, deeply focused on technological and innovative achievements, and latest trends of global investment and financing, shared latest China’s policies on pharmaceutical industry, discussed trends of global pharmaceutical innovative development in all respects. In addition, the 2021 CBIIC promoted global pharmaceutical innovative development and deepened cooperation between global capital and pharmaceutical innovation in a new era and a new pattern, helped unlock the full potential of pharmaceutical innovative vitality, promoted timely and efficient transformation of innovative results to products, to build a new future featuring pharmaceutical and innovative development and integration with capital.

The 7th China BioMed Innovation and Investment Conference

The 2023 China BioMed Innovation and Investment Conference (CBIIC) was successfully co-hosted by PhIRDA, HKEX, iMeta, and Ding Xin Pharmaceutical Innovation Research Center at Suzhou on March 29-31, 2023. Centering on the purpose of “Promote the Linkage between Social Capital and Innovation, Improve the Innovation Capability of Pharmaceutical Industry”, the 2023 CBIIC focused on industrial policies, latest global pharmaceutical R&D, and trends of investment and financing. The 2023 CBIIC was built as authoritative, professional, and multi-dimensional platform of exchanges and communications for leaders of pharmaceutical industry, experts, scholars, and domestic and international innovative enterprises and investors, to deepen the discussion about latest trends of innovative development, jointly consult new strategies for investment and cooperation. The 2023 CBIIC built a high-level platform of dialogue providing support for financing of innovative projects, improved the core innovative capabilities of China’s pharmaceutical industry, and facilitated the internationalization of innovative achievements.

The 8th China BioMed Innovation and Investment Conference

The 8th China BioMed Innovation and Investment Conference (CBIIC) was successfully held at Suzhou Industrial Park from September 25 to 27, 2023, guided by China Center for International Economic Exchanges (CCIEE), and co-hosted by PhIRDA, HKEX, iMeta, and Ding Xin Pharmaceutical Innovation Research Center. The 8th CBIIC further opened financing channel for pharmaceutical innovation, focused on China’s latest policies in pharmaceutical industry, explored the new trends of global pharmaceutical R&D and hot issues in investment and financing circle, shared opinions on China’s latest pharmaceutical industry policies and the trend of global pharmaceutical innovation. The discussions on related topics broadened the capital connection and innovation fields, built a high-level dialogue platform for more innovative projects to seek investment and partners, enhanced the core innovation capacity of China’s pharmaceutical industry, and drived domestic innovation to the global market.

The 9th China BioMed Innovation and Investment Conference

With the integration of industry and the emerging technologies, coupled with the rapid changes in geopolitical and economic landscapes, China’s pharmaceutical innovation finds itself at a crossroads of development once again. To build a multi-dimensional bridge and establish a diverse dialogue platform for the government, industry, academic, research, application and investment, the 2024 BioMed Innovation and Investment Conference (CBIIC) was held in Guangzhou from November 30 to December 2.
Based on China’s development with global vision, the 2024 CBIIC focused on new trends in global pharmaceutical R&D and hot topics in the investment and financing sectors. Leveraging the geographic advantages of the Greater Bay Area, the 2024 CBIIC provided opportunities for face-to-face communication for investors and roadshow speakers, achieving barrier-free and in-depth exchanges, and fostering more business opportunities for greater commercial value.